T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Apple
AAPL
|
+$4.53B |
| 2 |
Broadcom
AVGO
|
+$1.7B |
| 3 |
GE Vernova
GEV
|
+$1.29B |
| 4 |
International Paper
IP
|
+$1.11B |
| 5 |
Tesla
TSLA
|
+$956M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.44B |
| 2 |
NVIDIA
NVDA
|
+$2.09B |
| 3 |
Constellation Energy
CEG
|
+$1.9B |
| 4 |
Qualcomm
QCOM
|
+$1.84B |
| 5 |
Amazon
AMZN
|
+$1.56B |
Sector Composition
| 1 | Technology | 34% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Communication Services | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1126
HEICO Class A
HEI.A
$35.6B
| $8.57M | ﹤0.01% |
48,283
+1,072
| +2% | +$190K |
|
1127
Mohawk Industries
MHK
$8.52B
| $8.43M | ﹤0.01% |
74,219
+464
| +0.6% | +$52.7K |
|
1128
Oric Pharmaceuticals
ORIC
$1.04B
| $8.41M | ﹤0.01% |
1,189,227
-377,509
| -24% | -$2.67M |
|
1129
Annaly Capital Management
NLY
$14.2B
| $8.23M | ﹤0.01% |
431,884
+6,464
| +2% | +$123K |
|
1130
ArcBest
ARCB
$1.62B
| $8.23M | ﹤0.01% |
76,842
+56,182
| +272% | +$6.02M |
|
1131
Aecom
ACM
$16.9B
| $8.17M | ﹤0.01% |
92,710
+5,409
| +6% | +$477K |
|
1132
NeoGenomics
NEO
$1.04B
| $8.16M | ﹤0.01% |
588,594
-56,898
| -9% | -$789K |
|
1133
Freshworks
FRSH
$3.66B
| $8.16M | ﹤0.01% |
642,637
-388,416
| -38% | -$4.93M |
|
1134
Texas Pacific Land
TPL
$21.2B
| $7.96M | ﹤0.01% |
10,842
-43
| -0.4% | -$31.6K |
|
1135
AGCO
AGCO
$8.19B
| $7.95M | ﹤0.01% |
81,194
-4,464
| -5% | -$437K |
|
1136
Prime Medicine
PRME
$715M
| $7.95M | ﹤0.01% |
1,545,961
-976,629
| -39% | -$5.02M |
|
1137
Graco
GGG
$14B
| $7.93M | ﹤0.01% |
100,041
-87,313
| -47% | -$6.92M |
|
1138
Tarsus Pharmaceuticals
TARS
$2.09B
| $7.92M | ﹤0.01% |
291,275
-56,408
| -16% | -$1.53M |
|
1139
Amdocs
DOX
$9.26B
| $7.85M | ﹤0.01% |
99,421
+51,383
| +107% | +$4.06M |
|
1140
Voyager Therapeutics
VYGR
$234M
| $7.83M | ﹤0.01% |
989,549
-52,381
| -5% | -$414K |
|
1141
Jones Lang LaSalle
JLL
$14.9B
| $7.7M | ﹤0.01% |
37,481
+60
| +0.2% | +$12.3K |
|
1142
Thryv Holdings
THRY
$536M
| $7.62M | ﹤0.01% |
427,408
+3,698
| +0.9% | +$65.9K |
|
1143
Ocular Therapeutix
OCUL
$2.18B
| $7.6M | ﹤0.01% |
1,110,454
+447,782
| +68% | +$3.06M |
|
1144
AnaptysBio
ANAB
$564M
| $7.53M | ﹤0.01% |
300,224
+128,535
| +75% | +$3.22M |
|
1145
Rithm Capital
RITM
$6.58B
| $7.52M | ﹤0.01% |
689,390
+463,488
| +205% | +$5.06M |
|
1146
Twilio
TWLO
$16B
| $7.27M | ﹤0.01% |
127,940
+4,837
| +4% | +$275K |
|
1147
NorthWestern Energy
NWE
$3.48B
| $7.26M | ﹤0.01% |
144,955
+30,288
| +26% | +$1.52M |
|
1148
Spyre Therapeutics
SYRE
$896M
| $7.24M | ﹤0.01% |
307,976
+229,447
| +292% | +$5.4M |
|
1149
Old Republic International
ORI
$9.91B
| $7.21M | ﹤0.01% |
233,232
+17,002
| +8% | +$525K |
|
1150
Valmont Industries
VMI
$7.46B
| $7.2M | ﹤0.01% |
26,240
-689
| -3% | -$189K |
|